CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
Open Access
- 11 November 2025
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 141, 103046
Abstract
No abstract availableKeywords
This publication has 194 references indexed in Scilit:
- CAR T Cells and T-Cell Therapies for CancerJAMA, 2024
- Target selection and clinical chimeric antigen receptor T cell activity against solid tumorsiLABMED, 2023
- CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinomaEuropean Journal of Immunology, 2020
- Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatmentMedicinal Research Reviews, 2017
- Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinomaCancer Immunology, Immunotherapy, 2016
- Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TCancer Immunology, Immunotherapy, 2015
- High preoperative levels of serum glypican‐3 containing N‐terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomyInternational Journal of Cancer, 2015
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directionsHepatology, 2014
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- Expression of the MAGE gene family in human hepatocellular carcinomaCancer, 1999